Statistics for Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1
Total visits
| views | |
|---|---|
| Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1 | 0 |
Total visits per month
| views | |
|---|---|
| February 2026 | 0 |
| March 2026 | 0 |
| April 2026 | 0 |
| May 2026 | 0 |
| June 2026 | 0 |
| July 2026 | 0 |
| August 2026 | 0 |